GlycanAge® - What's Yours?
Dec 29 , 2020

GlycanAge® - What's Yours?

To address aging, we need to understand it. 

Why do some people stay healthy for their entire lives, while others do not? Many biomarkers can provide an estimate of our biological age. BioViva Science gives you access to the best among them. A recently developed biomarker that profoundly correlates with both disease-risk and lifestyle biomarkers is GlycanAge.™ This biomarker is based on glycans attached to immunoglobulin G (igG). Studies have demonstrated that glycan changes precede a plethora of age-related diseases. 

Watch BioViva's CEO, unbox GlycanAge.™ 

Glycans connected to IgG significantly change over time. Changes in glycosylation also appear to directly impact the function of our immune systems.

Decreases in IgG galactosylation was first observed several decades ago in patients with rheumatoid and osteoarthritis. This was reported in several subsequent studies, which associated it with the disease and its general progression. IgG galactosylation is also predictive of response to therapy. Perhaps most remarkable was the finding that a decrease in igG galactosylation preceded the onset of the disease by as much as several years (Lauc, 2016).

Declining IgG galactosylation was reported to not only associate with osteoarthritis and rheumatoid arthritis, but also with autoimmune diseases like Crohn’s disease, ulcerative colitis, systemic lupus erythematosus, coeliac disease, and several other serious diseases that afflict the human population, and for which there are (currently) no cures (Gudelj, 2018). More than half of the biological variation in chronological age is explainable with IgG glycans. Nevertheless, it is important to keep in mind that IgG glycans do not merely function as biomarkers but also as effectors that actively participate in the aging process.

Related to aging is the gradual decrease of igG galactosylation levels. In accordance with the inflammaging concept, this decrease is correlated with chronic low-grade sterile inflammation in elderly individuals that further exacerbates inflammation. Essentially, with this there is a feedback loop that is created that worsens the situation by the corresponding reaction of the immune system. In this process it is observed that the galactosylated IgG species represents both an aging biomarker and is a participant in its pathogenesis (Franceschi, 2000). 

It is imperative we understand our wellbeing, which is intimately connected with our biological age. GlycanAge™ is the first DTC glycan-based test that determines your biological age by, in essence, looking at the state of your immune system and inflammation.  The process is simple, and minimally invasive. Within a month, a lab will analyze the results. We will then review and discuss the results of the test and draft a plan for improving your overall health, as therapeutic interventions exist (e.g. extensive weight loss). 

GlycanAge™ is a premium investment, ensuring that we can further take ownership of our health and live the full and salubrious life that we deserve.

References and Suggested Reading

Lauc G, Pezer M, Rudan I, Campbell H. Mechanisms of disease: the human n-glycome. Biochim Biophys Acta. 2016; 1860:1574–82. PMID:26500099 

Gudelj I, Lauc G, Pezer M. Immunoglobulin G glycosylation in aging and diseases. Cell Immunol. 2018; 333:65–79. PMID:30107893

Franceschi C, Bonafè M, Valensin S, Olivieri F, De Luca M, Ottaviani E, De Benedictis G. Inflamm-aging. An evolutionary perspective on immunosenescence. Ann N Y Acad Sci. 2000; 908:244–54. PMID:10911963 


Authored by John Ryan

John Ryan is an independent writer and an avid enthusiast of biotechnology. He received his University education at Northern Michigan University, as a history major, where he was inducted into the Phi Beta Kappa Society for academic excellence. While in Michigan, he also trained as an athlete at the United States Olympic Education Center, where he achieved the status of a multiple-time University All-American in Greco-Roman wrestling. He has authored several plays and a collection of poetry. Some of his major areas of interests includes: Health, Finance, Literature, and Religious Studies. 

John is available to contact via email at:

Adam Alonzi

Adam Alonzi is a writer, biotechnologist, documentary maker, futurist, inventor, programmer, and author two novels. He is an analyst for the Millennium Project, and Head of Social Media and Content Creation for BioViva Sciences. Listen to his podcasts here. Read his blog here.